Consequently signatures aimed at identifying tumors with CYCLIN D activation, RB loss of function or CDK4 inactivation are being explored in clinical samples to distinguish those cancers that are sensitive or resistant to CDK4/6 inhibitor therapies [reviewed in 161]. Here, RB1 is linked to cancer.